List of Excipients in Branded Drug EMGALITY

Emgality Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Emgality is galcanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP). Its commercial formulation uses a conventional low-volume liquid biologic platform with histidine buffering, sodium chloride tonicity control, polysorbate 80 surfactant, and water for injection. The main excipient opportunities are not novel active ingredients. They are improvements in aggregation control, container-closure compatibility, device performance, cold-chain resilience, and biosimilar comparability.

The product has substantial commercial value because it is approved for migraine prevention and episodic cluster headache, uses self-administered subcutaneous delivery, and has an established prefilled-device franchise. FDA biologic exclusivity, formulation and device patents, manufacturing know-how, and regulatory complexity create barriers beyond the basic excipient composition.

What excipients are used in Emgality?

Emgality injection contains galcanezumab-gnlm at either 120 mg/mL or 100 mg/mL, depending on the presentation and market. The U.S. product is supplied primarily as single-dose prefilled pens and prefilled syringes, with a vial presentation also authorized for certain dosing needs.

The U.S. prescribing information identifies the following inactive ingredients:

Excipient	Primary function
L-histidine	Buffering agent
L-histidine hydrochloride monohydrate	Buffer capacity and pH control
Polysorbate 80	Surfactant and interfacial-stress protection
Sodium chloride	Tonicity adjustment
Water for injection	Vehicle

The formulation is adjusted to an acidic pH, approximately pH 5.5, consistent with a liquid subcutaneous monoclonal-antibody product designed for refrigerated storage and administration through a prefilled device (U.S. Food and Drug Administration [FDA], 2024).

Why does Emgality use histidine and polysorbate 80?

Histidine buffers are widely used in therapeutic antibodies because they can provide useful pH control without the precipitation and compatibility concerns associated with some phosphate systems. Polysorbate 80 reduces adsorption and aggregation caused by contact with air-liquid interfaces, glass, silicone oil, and device surfaces.

The excipient system must balance several requirements:

• Maintain antibody monomer content during refrigerated storage.
• Limit visible and subvisible particles.
• Protect against agitation during shipment.
• Preserve performance after transfer into a syringe or autoinjector.
• Avoid excessive viscosity during manual or automated injection.
• Maintain compatibility with glass, elastomer, silicone oil, and needle components.
• Support a commercially acceptable injection volume.

The formulation is therefore part of the product architecture, not merely a list of inactive ingredients.

What commercial opportunities exist in Emgality excipients?

The strongest opportunities are in specialty formulation materials, analytical testing, primary packaging, and delivery-device components. Commodity sodium chloride and water for injection provide limited differentiation. Histidine and polysorbate 80 provide more opportunity when supplied with pharmaceutical-grade documentation, low-bioburden controls, extractables data, and lot-to-lot consistency.

Excipient opportunity map

Opportunity	Commercial value	Main buyer
High-purity histidine and histidine hydrochloride	Medium	Biologic manufacturer and contract manufacturer
Low-peroxide polysorbate 80	High	Biologic developers and fill-finish providers
Polysorbate degradation monitoring	High	Quality-control laboratories and CDMOs
Protein-compatible surfactant alternatives	High	Biosimilar and lifecycle-management developers
Low-particle primary containers	High	Device and packaging suppliers
Silicone-oil optimization	High	Prefilled syringe and autoinjector manufacturers
Viscosity-reduction technology	High	High-concentration biologic developers
Lyophilization or liquid-stability platforms	Medium	Follow-on biologic developers
Excipient formulation screening	Medium	Biosimilar and reformulation programs
Container-closure extractables testing	Medium	Regulatory and quality organizations

Polysorbate 80 is the highest-value excipient category. Its degradation can generate free fatty acids, peroxide species, micelles, and particles. These degradation products may increase antibody aggregation or create visible and subvisible particulate matter. A supplier that can provide low-peroxide material, controlled fatty-acid composition, and validated stability data can compete on performance rather than price.

How strong is the Emgality formulation strategy?

The formulation is commercially strong because it supports a ready-to-use liquid product and self-administration. It does not require reconstitution, which reduces handling steps and supports prescription growth through retail and specialty-pharmacy channels.

The main technical constraints are:

1. Protein concentration. A 120 mg/mL antibody solution has materially higher viscosity and aggregation risk than a dilute laboratory formulation.
2. Subcutaneous injection. The formulation must pass through a small needle without excessive injection force.
3. Device contact. The antibody contacts glass, silicone oil, elastomers, and plastics.
4. Cold-chain exposure. The product must remain stable under refrigerated conditions and controlled short-duration excursions.
5. Agitation. Distribution and patient handling can expose the solution to shaking and repeated movement.
6. Particulate control. Monoclonal antibodies are sensitive to interfacial stress and container-related particles.

The formulation’s use of polysorbate 80 leaves room for lifecycle improvements. Potential modifications include optimized surfactant concentration, alternative polysorbates, nonionic surfactants with lower oxidation liability, or excipient combinations that reduce silicone-oil-induced aggregation. Any change would require comparative stability, immunogenicity, device, and clinical or bridging justification.

What formulations could compete with Emgality?

A competing or follow-on product could use the same active antibody with a materially different excipient system, provided the manufacturer demonstrates comparability and regulatory acceptability. The most commercially relevant formulation directions are:

Higher-concentration liquid formulations

A higher-concentration formulation could reduce injection volume or support less frequent administration. The tradeoff is higher viscosity, greater injection force, and increased sensitivity to aggregation. Such a product would require coordinated development of the formulation, needle gauge, syringe geometry, and autoinjector spring force.

Low-polysorbate formulations

A low-polysorbate or polysorbate-free formulation could reduce concerns about oxidation and particle formation. It would need an alternative strategy for protecting the antibody from air-liquid and solid-liquid interfaces.

Alternative surfactants

Poloxamers and other nonionic surfactants may be evaluated as alternatives or complements to polysorbate 80. The key screening criteria are antibody monomer retention, particle formation, oxidation, viscosity, device compatibility, and immunogenicity risk.

Lyophilized presentations

A freeze-dried product could improve long-term stability and reduce some liquid-phase degradation pathways. It would impose reconstitution requirements and would be less convenient than the existing prefilled pen or syringe. The commercial value is therefore limited unless it solves a meaningful stability or geographic-distribution problem.

Long-acting delivery systems

Depot formulations, wearable injectors, or implantable delivery systems could extend dosing intervals. These approaches face substantial development barriers because the antibody must remain stable during extended exposure to concentrated formulation environments and delivery-device materials.

What patents protect Emgality?

Emgality is a biologic, so its exclusivity profile differs from that of a small-molecule drug. Composition-of-matter, antibody-sequence, formulation, manufacturing, device, and method-of-use rights may all be relevant. FDA lists biologic licensing information in the Purple Book rather than the Orange Book (FDA, 2024).

The commercial protection layers are:

Protection layer	Relevance to Emgality
Antibody sequence and binding-site claims	Protect the galcanezumab molecule or closely related antibodies
Anti-CGRP use claims	Cover migraine prevention or cluster-headache treatment
Formulation claims	May cover buffer, surfactant, concentration, pH, or stability parameters
Manufacturing claims	May cover cell culture, purification, or antibody-production processes
Device patents	May cover pen, syringe, needle, or dose-delivery architecture
Regulatory exclusivity	Delays approval of a biosimilar application
Trade secrets	Protect process controls, analytical methods, and scale-up knowledge

Exact enforceability depends on claim scope, terminal disclaimers, prosecution history, post-grant proceedings, and the product claims actually listed or asserted. Excipient suppliers generally do not control market access unless their technology is covered by a blocking patent or incorporated into a proprietary delivery device.

When does Emgality lose exclusivity?

FDA approved Emgality on September 27, 2018, for the preventive treatment of migraine in adults. FDA later approved it for episodic cluster headache in 2019 (FDA, 2018, 2019).

As a licensed biologic, Emgality receives 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act. The statutory period therefore runs to approximately September 2030 for the original reference-product approval, subject to the regulatory treatment of subsequent supplements and applicable exclusivity determinations.

Patent expiry may extend beyond regulatory exclusivity. A biosimilar sponsor can file an application before regulatory exclusivity ends, but FDA approval cannot become effective until the applicable exclusivity period expires. Patent litigation, settlement terms, pediatric extensions, and patent-term adjustments can alter the practical launch date.

Exclusivity timeline

Event	Date
FDA approval for migraine prevention	September 27, 2018
FDA approval for episodic cluster headache	2019
Twelve-year reference biologic exclusivity	Approximately September 2030
Earliest practical biosimilar entry	Dependent on patents, litigation, and settlement
Small-molecule generic pathway	Not applicable

What is the Orange Book and Purple Book status of Emgality?

Emgality is regulated as a biologic and is identified through the FDA Purple Book framework. The Orange Book is principally used for approved small-molecule drugs and does not provide the principal patent-listing framework for a monoclonal antibody such as galcanezumab.

A biosimilar sponsor would use the abbreviated pathway under section 351(k) of the Public Health Service Act. The application would require analytical similarity, a tiered nonclinical and clinical package, immunogenicity assessment, and manufacturing comparability. Interchangeability would require a separate determination under the applicable FDA standard.

Which companies could challenge Emgality?

The likely challengers are large biosimilar developers and contract manufacturers with experience in monoclonal antibodies. Relevant capabilities include:

• Mammalian-cell expression and process development.
• Protein A and polishing chromatography.
• High-resolution mass spectrometry.
• Peptide mapping and glycan characterization.
• Charge-variant and size-variant analysis.
• Subvisible-particle testing.
• Immunogenicity testing.
• Prefilled-syringe and autoinjector assembly.
• Global regulatory submissions.

Potential competitive pressure is more likely to arise from the broader anti-CGRP class than from a single direct biosimilar entrant. Competing products include Aimovig, Ajovy, Vyepti, Nurtec ODT, and Qulipta. These products use different antibodies, peptides, or small molecules and compete on dosing frequency, oral administration, speed of effect, payer coverage, and patient adherence.

What generic or biosimilar launch risks exist?

The principal launch risks are technical and legal rather than excipient availability.

Technical risks

A biosimilar must match or closely align with Emgality across:

• Primary amino-acid sequence.
• Higher-order structure.
• Glycosylation profile.
• Charge variants.
• Aggregation and fragmentation.
• Potency and receptor binding.
• Formulation stability.
• Container-closure interaction.
• Immunogenicity.

A biosimilar can use different excipients, but the change may create additional analytical and clinical questions. The most defensible strategy is usually to reproduce the reference formulation where legally and technically feasible, then optimize only where the change creates a clear advantage.

Legal risks

Patent disputes may involve antibody sequence, epitope, manufacturing process, formulation, dosing, or device claims. The absence of an Orange Book listing does not eliminate patent risk. Biologic sponsors can enforce patents through ordinary patent litigation and the statutory information-exchange process applicable to biosimilar applications.

Commercial risks

A biosimilar entrant may face:

• Limited physician switching without interchangeability.
• Payer formulary barriers.
• Rebates from the reference sponsor.
• Patient preference for established autoinjectors.
• High manufacturing cost at relatively low injection volumes.
• Device-development delays.
• Need for multiple presentations to match the reference product.

How can excipient suppliers capture Emgality-related value?

The best commercial strategy is to sell an excipient package rather than a single raw material. A differentiated package would include:

1. Pharmaceutical-grade histidine and histidine hydrochloride.
2. Low-peroxide polysorbate 80.
3. Fatty-acid and peroxide characterization.
4. Lot-release specifications linked to antibody stability.
5. Extractables and leachables data.
6. Freeze-thaw and agitation studies.
7. Compatibility data with glass syringes and autoinjectors.
8. Technical support for biosimilar formulation development.
9. Regulatory documentation for U.S., European, and Asian submissions.

A supplier that can link excipient variability to antibody quality attributes has greater pricing power than a commodity supplier. The most valuable data are those that reduce development time or regulatory risk.

Geographic opportunities

The United States and European Union offer the largest commercial markets, but Asia-Pacific and Latin America create demand for formulations with longer temperature excursions and more flexible distribution. A formulation that can tolerate controlled room-temperature exposure, even for a limited period, could reduce logistics cost and improve access.

Any temperature-excursion claim must be supported by product-specific stability data. It cannot be inferred from the excipient composition alone.

How does Emgality compare with competing CGRP products?

Product	Active modality	Route	Typical dosing pattern	Excipient opportunity
Emgality	Anti-CGRP monoclonal antibody	Subcutaneous	Monthly, with loading dose for migraine	Liquid stability, device, biosimilar
Aimovig	Anti-CGRP-receptor monoclonal antibody	Subcutaneous	Monthly	Device and formulation competition
Ajovy	Anti-CGRP monoclonal antibody	Subcutaneous	Monthly or quarterly	High-concentration and long-interval delivery
Vyepti	Anti-CGRP monoclonal antibody	Intravenous	Quarterly infusion	Infusion formulation and container compatibility
Nurtec ODT	Small-molecule CGRP antagonist	Oral	Acute and preventive use	Taste masking, rapid disintegration
Qulipta	Small-molecule CGRP antagonist	Oral	Daily	Solid-dose formulation and bioavailability

Emgality’s principal formulation advantage is convenience through a ready-to-use subcutaneous presentation. Its principal vulnerability is competition from oral products and other antibodies offering different dosing intervals.

What is the revenue exposure for Emgality?

Emgality revenue is exposed to three factors: growth of the preventive migraine market, competition within the CGRP class, and future biosimilar price erosion. Lilly has reported Emgality as a growing product within its neuroscience portfolio, but the product competes in a crowded class with differentiated dosing and route options (Eli Lilly and Company, 2024).

The most important commercial defenses are:

• Sustained formulary access.
• Patient retention through device convenience.
• Expanded use in episodic cluster headache.
• Lifecycle improvements in injection experience.
• New delivery systems that preserve the antibody’s clinical profile.
• Manufacturing cost reductions before biosimilar entry.

An excipient change alone is unlikely to create a major revenue increase. Its value is higher when it enables a smaller injection, longer shelf life, reduced cold-chain dependence, lower injection force, or a differentiated device.

Key Takeaways

• Emgality uses galcanezumab in a liquid subcutaneous formulation based on histidine buffer, sodium chloride, polysorbate 80, and water for injection.
• Polysorbate 80 quality, degradation control, and device compatibility are the most attractive excipient opportunities.
• Emgality’s biologic exclusivity runs approximately through September 2030, while patent rights may extend beyond that date.
• The relevant FDA framework is the Purple Book and the 351(k) biosimilar pathway, not the conventional Orange Book generic pathway.
• Biosimilar competition will depend on antibody analytics, manufacturing scale, device replication, patent strategy, and payer contracting.
• The strongest lifecycle opportunities are higher-concentration formulations, improved injection devices, lower-particle systems, and longer temperature-excursion stability.
• Commodity excipient supply is less defensible than a validated formulation-and-device compatibility package.

FAQs

Can Emgality be reformulated without changing the active antibody?

Yes. A manufacturer can develop a different excipient system, but it must establish analytical comparability, stability, potency, immunogenicity risk, and device compatibility. The regulatory burden depends on whether the product is a reformulation, biosimilar, or new biologic product.

Is polysorbate 80 a patent barrier to Emgality biosimilars?

Usually, polysorbate 80 itself is not the principal barrier. The relevant risks are formulation claims that define specific concentrations, pH ranges, stability properties, or combinations with the antibody, together with device and manufacturing patents.

Could Emgality be converted to an oral product?

No direct conversion is commercially realistic because galcanezumab is a monoclonal antibody that would be degraded in the gastrointestinal tract. Oral CGRP products compete with Emgality through different small-molecule active ingredients.

Would a polysorbate-free Emgality formulation have commercial value?

Potentially. A polysorbate-free formulation could reduce surfactant oxidation and particle risk, but it would need to preserve antibody stability and device performance. The value would be greatest if it enabled longer shelf life, reduced immunogenicity concerns, or improved temperature tolerance.

What is the most attractive Emgality-related investment area?

The strongest opportunity is integrated biologic formulation and delivery technology, particularly low-peroxide surfactants, low-particle prefilled systems, viscosity-reduction platforms, and analytical services that support galcanezumab biosimilar development.

References

Eli Lilly and Company. (2024). 2024 annual report. https://investor.lilly.com/financial-information/annual-reports

U.S. Food and Drug Administration. (2018). FDA approves new treatment for patients with migraine. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine

U.S. Food and Drug Administration. (2019). Emgality prescribing information. https://pi.lilly.com/us/emgality-uspi.pdf

U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov

U.S. Food and Drug Administration. (2024). Emgality: Prescribing information. Eli Lilly and Company. https://pi.lilly.com/us/emgality-uspi.pdf